Alkermes Reaffirms Q4 Net Sales Guidance and Provides Alixorexton Phase III Timeline
Alkermes (ALKS) has reiterated its proprietary net sales outlook for the fourth quarter, projecting a range of $400 million to $420 million. This guidance provides continuity for investors following recent management updates regarding the company's financial trajectory. Looking toward long-term growth, the company is targeting mid-2027 for the release of Phase III clinical data for Alixorexton. The leadership team emphasized a strategic focus on navigating upcoming clinical milestones and optimizing current product performance to drive shareholder value.
Tickers: $ALKS